A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
Status:
Completed
Trial end date:
2020-06-09
Target enrollment:
Participant gender:
Summary
Bioequivalence study between two inhaler products (discus) of fixed dose combination of
fluticasone propionate and salmeterol xinafoate inhalation powder
Phase:
Phase 1
Details
Lead Sponsor:
Respirent Pharmaceuticals Co Ltd.
Collaborator:
Becro Ltd.
Treatments:
Charcoal Fluticasone Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance